• Citer

MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma

par Sadones, Jan;De Greve, Jacques;Neyns, Bart;Michotte, Alex ;In't Veld, Peter;Chaskis, Cristo;Sciot, Raf;Menten, Johan;Joossens, Eric J R;Strauven, Theo;D'Hondt, Lionel;Sartenaer, Daniel;Califice, Stéphane F E H S.F.E.H.;Bierau, Katja;Svensson, Cecilia
Référence European journal of cancer, 45, 1, page (146-153)
Publication Publié, 2009-01

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Aims: To investigate the correlation between O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and benefit from temozolomide in patients with recurrent high-grade glioma. Patients and methods: A real-time, quantitative, methylation-specific PCR assay was performed on archival tissue blocks from patients treated with temozolomide at the first recurrence. Results: A subgroup of 38 patients who were chemotherapy-naive at recurrence was analysed (22 glioblastoma, 12 anaplastic astrocytoma [AA] and 4 anaplastic oligoastrocytoma [AOA]); none had 1p/19q loss. Among 10 (26%) patients with a hypermethylated MGMT promoter, none experienced disease progression within the first two treatment cycles compared with 12 of 28 (43%) patients with an unmethylated promoter (p = 0.016). By Cox multivariate analysis, tumour grade and MGMT promoter methylation correlated with time to progression (p < 0.05); MGMT promoter methylation correlated with superior overall survival in AA/AOA but not in glioblastoma. Conclusions: MGMT promoter methylation predicted a survival benefit in patients with 1p/19q intact AA/AOA treated with temozolomide at recurrence. © 2008 Elsevier Ltd. All rights reserved.